Prevalence and association of thyroid disorders with selected risk factors and severity of disease in patients confirmed of Coronary Artery Disease

EM Samantha Bardara¹, Sagarika Ekanayake², Chandanie Wanigatunge³, Aruna Kapuruge⁴, GA Sarath Kumara⁵

Abstract:
Objective: Subclinical hypothyroidism (SCH) has been identified as a risk for atherosclerosis and Coronary Artery Disease (CAD). The aim of this study was to determine the prevalence and association between hypothyroidism or subclinical hypothyroidism (SCH) and lipid parameters, anthropometric data and the severity of coronary artery disease (CAD) in patients awaiting Coronary Artery Bypass Graft Surgery (CABG) from a selected center. Method: A cross sectional analytical study was carried out among patients awaiting CABG in a selected center. Thyroid profile (enzyme immunoassay method), lipoprotein (a) [Lp(a)], C-reactive protein (CRP) (immunoturbidimetric method) were determined and the Gensini score calculated. Lipid parameters and details of current medication were obtained from the medical records and anthropometric data were measured. Results: From a total of 102 patients 3% were on treatment for hypothyroidism and 15% had subclinical hypothyroidism. A significantly high (p = 0.04) percentage of SCH patients (75%) were dyslipidemic. There were no significant differences observed in lipid profiles and Lp(a) among SCH and euthyroid patients when the total sample or dyslipidemic sample was considered. However, a significantly high percentage (58%, p<0.05) of SCH patients on statins had a higher level of low density lipoprotein cholesterol (LDLc) compared to euthyroid dyslipidemic patients. A significant negative (p< 0.05) correlation was observed between thyroid stimulating hormone concentration and high density lipoprotein cholesterol (r= -0.67) in SCH group. No significant differences were observed in anthropometric data, CRP or Gensini score of SCH and euthyroid patients with CAD. Conclusion: The prevalence of dyslipidemia among SCH patients with CAD was significantly high. The patients suffering from SCH exhibited higher levels of LDLc compared to euthyroid patients from both the total and dyslipidemic groups. SCH patients under statin treatment displayed a higher LDLc suggesting a strong association between coronary artery disease and thyroid disease. Keywords: Subclinical hypothyroidism, hypothyroidism, coronary artery disease, lipid profile, anthropometric parameters, Gensini score, CRP

Introduction
Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide and coronary artery disease (CAD) has become one of the most prevalent conditions among South Asians¹. In Sri Lanka, the proportional mortality due to CAD is 25.7%². Atherosclerosis is the main cause for CAD and many biochemical [elevated homocysteine, fibrinogen, Lp(a), LDLc particle size and CRP] and other risk factors (diabetes, hypertension, obesity, sedentary

1. EM Samantha Bardara, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
2. Sagarika Ekanayake, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
3. Chandanie Wanigatunge, Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
4. Aruna Kapuruge, Cardiothoracic Unit, Sri Jayewardenepura General Hospital, Thalapathpitiya, Nugegoda, Sri Lanka.
5. GA Sarath Kumara, Cardiothoracic Unit, Sri Jayewardenepura General Hospital, Thalapathpitiya, Nugegoda, Sri Lanka.

Correspondence to: Sagarika Ekanayake, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. E-mail: sagarikae@hotmail.com
lifestyle, smoking, alcohol, family history of CAD, menopause and advancing age) are recognized as causes for the increased prevalence. Dyslipidemia characterized by elevated serum triglyceride (TG), elevated LDLc and reduced serum high density lipoprotein cholesterol (HDLc) is a hallmark of the disease. The CAD initiates at an early stage in life and continues throughout adulthood. The risk factors for CAD reported among Sri Lankans include, prevalence of hypercholesterolemia (>5.2 mmol/l), high LDLc (>3.4mmol/L), high TG (>1.7mmol/L) and low HDLc (<1.0 mmol/L) being 53.6%, 24.7%, 22.7% and 53.1% respectively.

Lipoprotein metabolism as well as some CVD risk factors are significantly affected by thyroid hormones, i.e: metabolism and production of adipokines, insulin sensitivity, oxidative stress and metabolic syndrome. Overt hypothyroidism is a well-established factor for atherosclerotic cardiovascular disease. Hypothyroidism increases athrogenic LDLc, induce diastolic hypertension, change coagulability and directly affect smooth muscle cells. Subclinical hypothyroidism, defined as mildly elevated thyroid stimulating hormone (TSH) with low to normal free tri-iodothyronine (fT₃) and free tetra-iodothyronine (fT₄), is also identified to be associated with risk of atherosclerosis and CAD. Significantly increased carotid artery intima thickness was reported with subclinical hypothyroidism compared to normal controls. The prevalence of SCH ranged between 4% - 10% in the general population and was between 7% - 26% in elderly. The prevalence of SCH in patients with dyslipidemia ranged between 1.4% - 26%. A population based cross sectional study of elderly women with subclinical hypothyroidism reported an age-adjusted prevalence of aortic atherosclerosis (odds ratio, 1.7 [95% CI, 1.1 to 2.6]) and myocardial infarction (odds ratio, 2.3 [CI, 1.3 to 4.0])

In contrast, some do not report an association between SCH and risk of atherosclerosis. Transient or persistent SCH was not associated with risk of CAD, heart failure or cardiovascular mortality in elderly. Therefore, consideration of subclinical hypothyroidism as a risk factor for ischemic heart disease is still debatable. However, as no data is available on thyroid functions of CAD patients in Sri Lanka, the aim of the present study was to determine the prevalence of hypothyroidism, SCH and effect of the thyroid function on lipid profiles and severity of CAD of dyslipidemic patients awaiting Coronary Artery Bypass Graft Surgery in a selected center.

**Method**

**Study population:** The research was conducted as a cross sectional study during 2013 and 2014. Study sample consisted of 67 males and 35 females awaiting CABG at the Cardiothoracic Unit, Sri Jayewardenepura General Hospital, Thalapathpitiya, Sri Lanka. All consenting patients referred to the centre for CABG were included until the sample size was fulfilled irrespective of other factors.

**Sample size:** The required sample size with an estimated prevalence of 30% CVD, at 95% significance level and 10% margin of error was 81. A study sample of 102 was enrolled.

**Thyroid profile assay:** Pre-operative blood samples (12 – 14 hour fasted) were collected. Serum was separated (3500 rpm, 5–10 min) and TSH, fT₃ and fT₄ were measured by enzyme immunoassay completion method by Mini-Vidas analyzer (Biomerieux, France).

**Lipoprotein(a) assay:** Lp(a) content was measured by an immunoturbidimetric method (Thermo Scientific, Finland) with pre-operative blood samples. The absorbance of the immune-complex, produced from Lp(a) and anti-serum was measured at 340 nm by Konelab 20XT (Thermo Scientific, Finland).

**CRP assay:** CRP was measured using turbidimetric immunoassay (Biolabo, France) using Konelab 20XT (Thermo Scientific, Finland) on pre-operative blood samples. The absorbance at 340 nm was measured against the absorbance of standard.

**Lipid profile and data from data records:** Data on total cholesterol (TC), LDLc, HDLc, TG were collected from each patient’s data records and TC: HDLc ratio calculated. The lipid profile was analysed at the enrolment of patients for surgery. Information related to dyslipidemia and hypothyroidism was also gathered from data records of respective patients.

**Anthropometric parameters:** Weight and height were measured by weighing scale (Health scale, China) and stadiometer respectively. Waist, hip and midarm circumference were measured using non-stretchable tape. Body mass index (BMI) and the waist to hip ratio were calculated.

**Gensini score:** The Gensini score system was used to evaluate the severity of CAD from coronary angiography. The data of coronary angiography were gathered from the medical records of patients. The Gensini score was computed by assigning a severity score according to the degree of luminal narrowing and geographical importance of each coronary stenosis.
Ethics approval and consent to participate: The study was approved by Ethics Review Committees of Faculty of Medical Sciences, University of Sri Jayewardenepura (635/12) and Sri Jayewardenepura General Hospital, Thalapathpitiya, Sri Lanka. Written informed consent was obtained after explaining the purpose of the study to each volunteer prior to commencement of the study.

Statistical Analysis: All statistical analyses were carried out using SPSS version 16.0 (2007, SPSS for Windows, SPSS Inc., Chicago, IL, USA) package. The results were expressed as mean ±1 standard deviation and the p value of less than 0.05 considered significant. Non-parametric significances were analysed by Mann-Whitney U test. Correlations were analysed by Spearman test.

Results
The average ages of male and female patients were 56.9 ±10 and 57.8 ±7 respectively. From the total sample 15% (n=15) of individuals were SCH and not previously diagnosed. The age distribution of SCH patients was 39 to 63 years. Distribution of SCH was significantly (p=0.04) high among males (17.9%) compared to females (11.4%). The 3% of patients diagnosed as hypothyroid were on treatment with L-thyroxin.

From the study sample 87.3% (n=89) of individuals had a history of dyslipidemia and were on statins treatment (majority under the treatment of 20 mg or 40 mg (60%) of atorvastatin). When considering the dyslipidemic (n=89) patients 13.5% of them were SCH.

Table 1 shows the values of thyroid profile (TSH3, fT3, fT4), lipid profile (TC, LDLc, HDLc, TG, TC: HDLc ratio), Lp(a), CRP, BMI, waist circumference, waist to hip ratio, mid arm circumference and Gensini score of euthyroid and SCH individuals of the total sample and dyslipidemic individuals. The average values for fT3 and LDLc levels of hypothyroid patients were 3.5±0.8 nmol/L and 121±43 mg/dL respectively. Hypothyroid individuals (n=3) were excluded in the analyses.

Apart from the TSH concentration no significant differences were observed in thyroid profiles, lipid profiles, Lp(a), CRP, BMI, waist circumference, waist to hip ratio, mid arm circumference and Gensini score among SCH and euthyroid patients when total sample or dyslipidemic sample was considered. However, when considering the LDLc concentrations of SCH or euthyroid dyslipidemic patients under statins, 30% of patients had higher levels above normal reference value of <100 mg/dL [3]. There was a significant association (p= 0.04) between SCH and desirable level of LDLc (< 100 mg/dL) concentration of dyslipidemic patients on statins. Majority of SCH patients (58%; 7/12) had LDLc concentrations above 100 mg/dL. Dyslipidemic SCH patients were on atorvastatin of 20 mg (80%) and 40 mg (20%). Among euthyroid patients with CAD, only 26% (20 out of 75) had LDLc> 100mg/dL. A non-significant (p> 0.05) positive correlation was observed between TSH and TC: HDL (r=0.5), and a significant negative correlation between TSH with HDL (r= 0.67) in SCH group.

Discussion
The present study intended to study the prevalence of SCH and its association with risk of atherosclerosis in a cohort of individuals with confirmed CAD as data are not available for Sri Lankans and to observe parallels with reported data for South Asian and other populations. In the present study SCH was considered as TSH> 5 mIU/L as it is the upper limit of the reference range21. Among the dyslipidemic individuals, 13.5% were found to be SCH based on diagnosis criteria9. Similarly an Indian study revealed the prevalence of SCH among dyslipidemics as 14.7%22. When all SCH patients in this study were considered the prevalence of dyslipidemia among them was 80% (12 of 15). The prevalence of dyslipidemia and subclinical hypothyroidism in the United States was 53%23 and 4.3%24 respectively and the dyslipidemic with SCH were 83% and the study concluded that SCH was associated with high prevalence of dyslipidemia and CAD9. Present prevalence data on dislipidemic with SCH compares well with observations of above studies.

L-thyroxin replacement therapy on lipid based cardiovascular risk in SCH has shown that the changes of lipid profile due to mild elevation of TSH have been rendered with the treatment25. According to an Indian study low HDLc, high serum TC and LDLc were found in patients with TSH above 10 mIU/L who were not on statins22. In a study conducted among both groups of individuals with arterial fibrillation (symptomatic and asymptomatic) when combined SCH have been revealed that increased level of TC, LDL, TG, atherogenicity and decreased level of HDL compared to control group26. In contrast, Mahajan et al (2018) has reported a normal homeostatic and metabolic function in both SCH and overt hypothyroid patients compared to control group27. However in the present study such
Table 01 Thyroid profile, lipid profile, Lp(a) and other parameters of total, SCH and euthyroid individuals

| Measurements            | Total sample (n=102) | Total sample (n=99*) | p value | Dyslipidemic group (n=87*) | p value | Reference ranges |
|-------------------------|----------------------|----------------------|---------|---------------------------|---------|-----------------|
|                         | Total sample (n=99)  | SCH (n=15)           | (range: 4.5–27.1) | Euthyroid (n=84)           |         |                 |
| TSH3 (µIU/mL)           | 3.2 ± 3.9            | 7.9 ± 6.3            | 0.003   | 8.7 ± 7.0                 | 0.000   | 0.4-4.5 *       |
|                         | (range: 4.5–27.1)    | 2.0 ± 1.0            |         | (range: 5–27.1)           |         |                 |
| FT3 (nmol/L)            | 3.9 ± 1.1            | 4.3 ± 1.0            | 0.13    | 4.1 ± 1.0                 | 0.5     | 3.5-7.8 *       |
|                         | 3.8 ± 1.1            | 3.8 ± 1.1            |         | 3.9 ± 1.1                 | 0.5     |                 |
| FT4 (pmol/L)            | 15.2 ± 3.4           | 14.9 ± 1.4           | 0.19    | 14.8 ± 0.8                | 0.5     | 9.0-25 *        |
|                         | 15.3 ± 3.4           | 15.3 ± 3.4           |         | 15.1 ± 3.3                | 0.5     |                 |
| Lp(a) (mg/dL)           | 50 ± 38              | 48.0 ± 38.0          | 0.72    | 38.0 ± 21.3               | 0.2     | < 30 *          |
|                         | 50.2 ± 3.9           | 50.2 ± 3.9           |         | 52.3 ± 4.0                | 0.2     |                 |
| TC (mg/dL)              | 150 ± 36             | 152.1 ± 40.5         | 0.70    | 158.7 ± 35.9              | 0.3     | < 200 *         |
|                         | 150.0 ± 35.3         | 150.0 ± 35.3         |         | 151.2 ± 36.6              | 0.5     |                 |
| LDLc (mg/dL)            | 92 ± 36              | 91.9 ± 35.1          | 0.5     | 92.5 ± 35                 | 0.5     | < 100 *         |
|                         | 89.5 ± 29.4          | 89.5 ± 29.4          |         | 91.0 ± 30.0               | 0.5     |                 |
| HDLc (mg/dL)            | 34 ± 9               | 38 ± 9.2             | 0.13    | 38.0 ± 10.0               | 0.2     | < 40 *          |
|                         | 33.1 ± 9.5           | 33.1 ± 9.5           |         | 33.7 ± 9.6                | 0.2     |                 |
| TG (mg/dL)              | 133 ± 60             | 118.5 ± 28.3         | 0.08    | 120.2 ± 30.6              | 0.4     | < 150 *         |
|                         | 134.5 ± 63.7         | 134.5 ± 63.7         |         | 135.1 ± 62.4              | 0.4     |                 |
| TC : HDLc               | 4.6 ± 1.2            | 4.1 ± 1.1            | 0.47    | 4.3 ± 1.2                 | 0.7     | < 5 *           |
|                         | 4.6 ± 1.2            | 4.6 ± 1.2            |         | 4.6 ± 1.2                 | 0.7     |                 |
| CRP (mg/L)              | 7 ± 8                | 6.3 ± 5.9            | 0.70    | 7.2 ± 6.4                 | 0.9     | < 6 *           |
|                         | 6.9 ± 8.6            | 6.9 ± 8.6            |         | 7.4 ± 9.1                 | 0.9     |                 |
| BMI (kg/m²)             | 24.8 ± 3.8           | 25.1 ± 4.3           | 0.89    | 25.5 ± 4.2                | 0.8     |                 |
|                         | 24.9 ± 3.6           | 24.9 ± 3.6           |         | 25.1 ± 4.3                | 0.8     |                 |
| Waist circumference     | 94.5 ± 9.2           | 92.7 ± 11.7          | 0.48    | 94. ± 11.2                | 0.6     |                 |
|                         | 95.0 ± 8.9           | 95.0 ± 8.9           |         | 95.3 ± 8.6                | 0.6     |                 |
| Waist: hip ratio        | 1.0 ± 0.06           | 0.9 ± 0.08           | 0.53    | 1.0 ± 0.09                | 0.98    |                 |
|                         | 1.01 ± 0.06          | 1.01 ± 0.06          |         | 1.0 ± 0.05                | 0.98    |                 |
| Mid arm circumference   | 27.5 ± 3.1           | 27.2 ± 3.8           | 0.91    | 27.7 ± 4.0                | 0.8     | < 24            |
|                         | 27.5 ± 2.9           | 27.5 ± 2.9           |         | 27.7 ± 2.9                | 0.8     |                 |
| Gensini score           | 48 ± 26              | 49 ± 26              | 0.57    | 46.3 ± 27.8               | 0.9     |                 |
|                         | 47.7 ± 25.0          | 47.7 ± 25.0          |         | 47.8 ± 24.6               | 0.9     |                 |

*aManual of standard operation procedure, sample collection and reference range for clinical chemistry, World Health Organization, Ministry of Health and the Department of Biochemistry, Medical Research Institute, Sri Lanka. *bReference range as per lipoprotein(a) kit. *cThird Report of the National Cholesterol Education Programme (Adult Treatment Panel III), 2002.

* Hypothyroid patients were excluded in the analyses.

Differences in lipid profile of euthyroid and SCH patients were not observed. This may be due to all dyslipidemic patients being on statins treatment or due to the small sample size. The percentage of the SCH individuals who had LDLc concentration >100 mg/dL was significantly (p=0.04) high compared to dyslipidemic euthyroid patients. This reflects clearly the ineffectiveness of statins treatment without treating SCH and susceptibility of SCH individuals to develop dyslipidemia. Further, in such patients continuous monitoring of LDLc is important in preventing further complications. It is essential that such patients are made aware of the importance of compliance with continuous monitoring of the lipid profile and the necessity to change the drug dose accordingly.

Serum TSH had positively correlated with TC and LDLc in SCH individuals. However, serum TSH of SCH individuals of present study had significant negative correlation with HDLc and a non-significant positive correlation with TC: HDL ratio. This suggests that contribution to increasing HDLc is a factor to be considered among the SCH patients in Sri Lanka.

CRP is a predictor of risk of MI, stroke or peripheral vascular disease in asymptomatic individuals of CHD. In the present study there was no any significance different observed among total and dyslipidemic euthyroid between SCH patients. Though CRP is reported as elevated in patients with familial hypercholesterolemia, correlations of CRP with any of the lipid parameter or Lp(a) was not observed in this study. Analysis with high sensitivity CRP may overcome the lack of correlations.
no significant differences were observed among total and dyslipidemic euthyroid and SCH patients. A retrospective study conducted among apparently healthy individuals also reported no significant differences of BMI and waist circumferences among euthyroid and SCH individuals33. The study had analyzed the incidence of CAD (presence of plaques), obstructive CAD (stenosis ≥ 50% -calculated by Coronary Computed Tomography angiography) and coronary artery calcium score of SCH and euthyroid patients. The SCH group had significantly high value for coronary artery calcium score compared to the euthyroid group. The incidence of CAD and coronary artery calcium score >100 were also significantly high among SCH male compared to euthyroid male. However, the obstructive CAD was not significantly different33. In the present study all of the individuals were CAD and Gensini score was not significantly different between SCH and euthyroid individuals. Another retrospective study with the patients of acute coronary syndrome who underwent angiography had revealed SCH group had greater incidence of multi vessel disease (18 vs. 12, \( p = 0.1904 \)). The study concluded SCH is not an independent risk factor for early occurrence of CAD and is not associated with severity and angiographic pattern of CAD34. Another study also concluded that CAD events or CAD mortality were not associated with thyrotropin levels within the reference ranges35. SCH individuals had also exhibited increased concentration of Lp(a)36. Elevated Lp(a) concentration in hypothyroid patients had normalized on L-thyroxin replacement therapy37 and some studies reported no effect on treatment with L-thyroxin on Lp(a)38. In the present study Lp(a) concentration was not significantly different between euthyroid and SCH individuals. Thus compared to lipid parameters, elevated Lp(a) singles out as an independent risk factor39.

Conclusions

According to these observations we can conclude that the prevalence of subclinical hypothyroidism among CAD patients was 15%. The patients suffering from SCH exhibited higher levels of LDLc compared to euthyroid patients from both the total and dyslipidemic groups. SCH patients under statin treatment displayed higher LDLc suggesting a strong association between coronary arterial disease and thyroid disease. Screening of CAD patients for SCH and treatment may be beneficial in achieving target level of LDLc with statins treatment. Thus individuals identified as subclinical hypothyroid or hypothyroid should be made aware of their susceptibility to develop CAD if other modifiable and non-modifiable risk factors are prevalent as the above conditions afflict a certain percent of the population.

Availability of data and material

The data of the patients included in the above study are available with the principal author. The data are part of the authors’ postgraduate research work.

Conflict of interest statement

The authors declare that they have no conflict of interests.

Funding

This work was supported by a grant from the National Science Foundation (NSF/RG/2011/HS/18) Sri Lanka.

Authors’ contributions

E.M.S. Bandara acquired data and analyzed the data, S. Ekanayake designed the study and drafted the manuscript for important intellectual content, C.A. Wanigatunge designed the study and revised the manuscript critically, A. Kapuruge designed the study and revised the manuscript critically, G. A. S. Kumara designed the study and assisted in acquiring data. All authors read and approved the final manuscript.

Acknowledgements

We would like to extend our gratitude to the patients who consented to be part of this study and staff and colleagues of the Cardiothoracic Unit, Sri Jayewardenepura General Hospital and Department of Biochemistry, University of Sri Jayewardenepura, Sri Lanka for their support.
Prevalence and association of thyroid disorders with selected risk factors and severity of disease in patients confirmed of CAD

References:
1. Enas EA, Chacko V, Pazhoor SG, Chennikkara H, Devarapalli HP. Dyslipidemia in South Asian patients. Curr. Atheroscler. Rep. 2007; 9 (5):367–74.
2. World health ranking, Health profile-Sri Lanka. World Health Organization, 2014. http://www.worldlifeexpectancy.com/country-health-profile/sri-lanka Accessed on 16th August 2016.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106:3134-421.
4. McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE and Strong JP. Origin of atherosclerosis in childhood and adolescence. Am. J. Clin.1 Nutr. 2000; 72 (5):1307-15.
5. Herath HRISI, Katulanda P, Matthews DR, et al. Prevalence and patterns of dyslipidemia among adult Sri Lankans. Sri Lanka Medical Association - 123rd Annual Scientific Sessions. 2010:15.
6. Duntas LH. Thyroid disease and lipids. Thyroid. 2002; 12 (4): 287-93.
7. Lee JJ, Pedley A, Marqusee E, Sutherland P, Hoffmann U, Massaro JM, et al. Thyroid function and cardiovascular disease risk factors in euthyroid adults: a cross-sectional and longitudinal study. Clin Endocrinol. 2016; 85 (6): 932–41.
8. Cappola AR and Ladenson PW. Hypothyroidism and atherosclerosis. J. Clin. Endocrinol. Metab. 2003; 88 (6): 2438–44.
9. Mya MM, Aronow WS. Subclinical Hypothyroidism Is Associated With Coronary Artery Disease in Older Persons. J Gerontol A BiolSci Med Sci. 2002; 57 (10): 658-59.
10. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2004; 89 (5): 2099–106.
11. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA.2004; 291 (2): 228–38.
12. Mohanty S, Amruthhal W, Reddy GC, Kusumanjali G, Kanagasabapathy AS, Rao P. Diagnostic strategies for subclinical hypothyroidism. Indian J Clin Biochem.2008; 23 (3): 279-82.
13. Pearce EN. Hypothyroidism and Dyslipidemia: Modern Concepts and Approaches. CurrrCardiol Rep.2004; 6 (6): 451-6.
14. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, and Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 2000; 132 (4): 270–8.
15. Almeida CA, Teixeira PFDS, Soares DV, Cabral MD, Costa SM, SallesEF, et al. Carotid intima-media thickness as a marker of cardiovascular risk in patients with subclinical hypothyroidism. Arq Bras EndocrinolMetab. 2007; 51 (3): 472–7.
16. Cabral MD, Teixeira PFS, Silva NAO, Morais FCC, Soares DV, Salles E, et al. Normal flow-mediated vasodilatation of the brachial artery and carotid artery intima-media thickness in subclinical hypothyroidism. Braz. J. Med. Biol. Res. 2009; 42 (5): 426–32.
17. Hyland KA, Arnold AM, Lee JS and Cappola AR. Persistent Subclinical Hypothyroidism and Cardiovascular Risk in the Elderly: The Cardiovascular Health Study. J Clin Endocrinol Metab. 2013; 98 (2):533–40.
18. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults. JAMA. 2006; 295 (9):1033–41.
19. World Health Organization. Noncommunicable diseases country profiles. 2011. WHO Document Production Services, Geneva, Switzerland.
20. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am JCardiol. 1983;51 (3): 606.
21. Manual on Standard operation procedure, sample collection and reference range for clinical chemistry, World health Organization, 2004 – 2005. https://www.google.lk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKFwje7rO9_XQAhUGso8KHVnzAakQFggZMAA&url=https%3A%2F%2Fwww.scribd.com%2Fdoc%2F19145589%2FManual-on-Standard-Operation-Procedures-Sample-Collection-and-Reference-Ranges-for-Clinical-Chemistry&usg=AFQjCNGeX6BfrKT_7oq-BDp7TCD7EC_.JA Accessed on 19th March 2013.
22. Marwaha RK, Tandon N, Garg MK, Kanwar R, Sastry A, Narang A, et al. Dyslipidemia in subclinical hypothyroidism in an Indian population. ClinBiochem. 2011; 44 (14-15): 1214–17.
23. Töth PP, Potter D, Ming EE, Roger VL, Go AS, Lloyd-Jones DM, et al. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2011; 6 (4): 325–30.
24. Hollowell JG, Staehling NW, Flanders WD, Hannon WH,
Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J. Clin. Endocrinol. Metab.* 2002; 87 (2): 489–99.

25. Franklyn JA, Daykin J, Betteridge J, Hughes EA, Holder R, Jones SR, et al. Thyroxine replacement therapy and circulating lipid concentrations. *Clin Endocrinol (Oxf)*. 1993; 38 (5): 453-9.

26. Rakhmatullov R, Rakhmatullov A, Rakhmatullov F, Burnmistrova L and Moiseeva I. Thyroid status in the combination of atrial fibrillation with subclinical thyrotoxicosis. *Bangladesh J. Med. Sci.* 2019; 18 (2), 402-410.

27. Mahajan A, Mahaur R, Singh T, Jain A, Dhanwal D, and Gupta M. Haemostatic functions and metabolic profile of subclinical hypothyroid and hypothyroid patients. *Bangladesh J. Med. Sci.* 2018; 17(4), 532-536.

28. Shekhar R, Chowdary NVS, Das MC, Vidyad Prabodh S. Prevalence of subclinical hypothyroidism in coastal Andhra Pradesh. *Biomed Res.* 2011; 22 (4): 471-4.

29. Rifai N, Joubran R, Yu H, Asmi M., and Jouma M. Inflammatory Markers in Men with Angiographically Documented Coronary Heart Disease. *Clin. Chem.* 1999; 45 (11): 1967–73.

30. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *BMJ.* 2000; 321 (7255): 199–204.

31. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM. et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. *Eur. Heart J.* 2000; 21 (19): 1584–90.

32. Mohrschladt MF, de Maat MP, Westendorp RG. and Smelt AH. C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy. *Atherosclerosis.* 2001; 157 (2): 491–4.

33. Park YJ, Lee YJ, Choi SI, Chun EJ, Jang HC, Chang HJ. Impact of subclinical hypothyroidism on the coronary artery disease in apparently healthy subjects. *Eur J Endocrinol.* 2011; 165 (1): 115–21.

34. Soman B, Rahaman MA and Vijayaraghavan G. Subclinical Hypothyroidism and Coronary Artery Disease: Comparative study of the Angiographic Disease Pattern in Indian Women. 7th National Annual Conference of Indian Association of Clinical Cardiologists, Jharkhand, India. September 2016. [https://www.researchgate.net/publication/308693776_Subclinical_Hypothyroidism_and_Coronary_Artery_Disease_Comparative_study_of_the_Angiographic_DiseasePattern_in_Indian_Women.](https://www.researchgate.net/publication/308693776_Subclinical_Hypothyroidism_and_Coronary_Artery_Disease_Comparative_study_of_the_Angiographic_DiseasePattern_in_Indian_Women. Accessed on 15th Jan 2017.

35. Åsvold BO, Vatten LJ, Bjørø T, Bauer DC, Bremmer A, Cappola AR, et al. Thyroid Function Within the Normal Range and Risk of Coronary Heart Disease. *JAMA Intern Med.* 2015; 175 (6):1037.

36. Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktari ET, Elisaf MS, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? *Eur J Endocrinol.* 2001; 145 (6): 705–10.

37. Becerra A, Bellido D, Luengo A, Piédrola G, and De Luis D. A. (1999). Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. *Clin Nutr.* 1999; 18 (5): 319–22.

38. Pazos F, Alvarez JJ, Rubiés-Prat J, Varela C, and Lasunción MA. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. *J. Clin. Endocrinol. Metab.* 1995; 80(2): 562–6.

39. Bandara EMS, Ekanayake S, Wanigatunge CA, and Kapuruge A. Lipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft: a cross sectional study. *BMC CardiovascDisord.* 2016; doi:10.1186/s12872-016-0393-1.